VectivBio initiates phase 3 trial of apraglutide in patients with short bowel syndrome
VectivBio, a leading Swiss biotechnology firm, has announced the commencement of patient dosing in its phase 3 STARS…
Jazz Pharmaceuticals to acquire GW Pharmaceuticals in $7.2bn deal
In a significant move within the pharmaceutical industry, Irish biopharma company Jazz Pharmaceuticals has announced an agreement to…
Bexson Biomedical raises $4.8m to advance wearable ketamine treatment for pain and mental health disorders
Bexson Biomedical has successfully raised $4.8 million in Series A funding to accelerate the development of its subcutaneous…
Horizon Therapeutics announces $3.05bn acquisition of Viela Bio to expand rare disease pipeline
In a major move to strengthen its leadership in rare diseases, Horizon Therapeutics, an Irish biopharmaceutical company, has…
Amgen secures breakthrough therapy designation for sotorasib in China
Amgen has achieved a major milestone in the global development of its investigational KRAS G12C inhibitor, sotorasib, with…
Nordic Capital proposes $846m acquisition of Advanz Pharma
In a significant move within the pharmaceutical industry, Nordic Capital has made a formal offer to acquire Advanz…
FDA approves Opdivo and Cabometyx combo for advanced kidney cancer treatment
The U.S. Food and Drug Administration (FDA) has officially approved the combination of Bristol Myers Squibb’s Opdivo (nivolumab)…
ViiV Healthcare’s Cabenuva secures FDA approval for HIV treatment
ViiV Healthcare has received FDA approval for Cabenuva, a long-acting treatment regimen for HIV-1 infection in adult patients.…
Eli Lilly completes $1.04bn acquisition of Prevail Therapeutics to expand gene therapy program
Eli Lilly and Company has officially finalized its acquisition of Prevail Therapeutics in a deal valued at up…
BirchBioMed reports breakthrough phase 2 trial results for FS2 in treating keloid scars
BirchBioMed, a Canadian clinical-stage immunology company, has unveiled promising results from a phase 2 trial of FS2, its…